Eli Lilly And Co vs Petróleo Brasileiro SA — how do they compare? Eli Lilly And Co trades at $1,220.93 (market cap $1.08T), while Petróleo Brasileiro SA trades at $17.91 (market cap $112.19B). The key difference: Eli Lilly And Co is far larger — about 9.6× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.42%). Which is the better fit depends on your goals.
| LLY | PBR | |
|---|---|---|
Market Cap | $1.08T | $112.19B |
Sector | Health | Technology |
52-Week High | $1.24K | $22.03 |
52-Week Low | $639.43 | $11.54 |
Enterprise Value | $1.13T | $172.61B |
Dividend Yield | 0.57% | 9.42% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Petrobras (PBR) trades at $17.93, down 2.18% today, showing strong fundamentals with a P/E of 4.53 and robust profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $1.60 versus $1.40 expected, driven by record production and higher oil prices. Technical indicators signal bearish momentum, with RSI at oversold levels near 20.31, while analyst consensus remains positive with 50% buy ratings.
The outlook remains favorable due to cheap valuations and production growth, but risks include regulatory uncertainty and volatile oil prices. Investment opportunity lies in sustained dividend payments and operational efficiency, though geopolitical and macroeconomic factors could pressure near-term performance.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →